DBV Technologies S.A. (DBVT) and Anchiano Therapeutics Ltd (NASDAQ:ANCN) Comparison side by side

Since DBV Technologies S.A. (NASDAQ:DBVT) and Anchiano Therapeutics Ltd (NASDAQ:ANCN) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation of both companies.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
DBV Technologies S.A. N/A 0.00 N/A -3.27 0.00
Anchiano Therapeutics Ltd N/A 0.00 13.28M -5.96 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for DBV Technologies S.A. and Anchiano Therapeutics Ltd.


Table 2 shows us the return on equity, return on assets and net margins of both companies.

Net Margins Return on Equity Return on Assets
DBV Technologies S.A. 0.00% 0% 0%
Anchiano Therapeutics Ltd 0.00% 0% 0%

Analyst Recommendations

The table delivered features the ratings and recommendations for DBV Technologies S.A. and Anchiano Therapeutics Ltd.

Sell Ratings Hold Ratings Buy Ratings Rating Score
DBV Technologies S.A. 0 4 3 2.43
Anchiano Therapeutics Ltd 0 0 1 3.00

DBV Technologies S.A.’s upside potential is 108.37% at a $17.17 consensus target price. On the other hand, Anchiano Therapeutics Ltd’s potential upside is 128.90% and its consensus target price is $16. Based on the analysts belief we can conclude, Anchiano Therapeutics Ltd is looking more favorable than DBV Technologies S.A.

Institutional & Insider Ownership

DBV Technologies S.A. and Anchiano Therapeutics Ltd has shares held by institutional investors as follows: 46.32% and 0%. Insiders Competitively, held 23.75% of Anchiano Therapeutics Ltd shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
DBV Technologies S.A. 14.14% 33.93% -42.2% -59.41% -57.97% 40.81%
Anchiano Therapeutics Ltd -4.53% 0% 0% 0% 0% -25.83%

For the past year DBV Technologies S.A. had bullish trend while Anchiano Therapeutics Ltd had bearish trend.


DBV Technologies S.A. beats Anchiano Therapeutics Ltd on 3 of the 5 factors.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which is in Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow’s milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen’s egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage product development programs include treatments for Crohn’s disease and respiratory syncytial virus. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.